EpiPen-Maker Won’t Testify At Senate Hearing
Mylan says it is refusing the committee's request because of the pending settlement and no one from CMS or the Justice Department will be attending.
Mylan Refuses To Testify At Senate Hearing About EpiPen Costs To Medicaid
In a move that angered a key Senate lawmaker, Mylan Pharmaceuticals has declined to testify at a planned Nov. 30 Senate hearing to review a $465 million settlement the drug maker purportedly reached with the US Department of Justice for shortchanging Medicaid. In a letter to Sen. Chuck Grassley (R-Iowa), who chairs the Senate Judiciary Committee, an attorney for Mylan explained the company will not appear for three reasons – the “stated focus of the hearing,” because the hearing involves a “pending matter,” because both the Justice Department and the Centers for Medicare & Medicaid Services have already said they will not send officials to testify. (Silverman, 11/21)
The Associated Press:
EpiPen Manufacturer Will Be A No-Show At Senate Hearing
Pharmaceutical company Mylan is refusing to testify at a congressional hearing next week on a settlement between the company and the Justice Department over its life-saving EpiPen. In a letter to the Senate Judiciary Committee, an attorney for Mylan said company executives wouldn't testify at the Nov. 30 hearing because the settlement is a pending matter and the Justice Department would also not be attending. (Jalonick, 11/21)